Vaccini Astrazeneca e Johnson & Johnson: “In about 9 out of 10 cases, cerebral venous sinus thrombosis (TSVC) presents with headache of particular intensity, which patients generally report as” never experienced before. ” This is one of the main symptoms that suggest a rare thrombotic event, as illustrated in the document published by Aifa on “Post-vaccination thromboembolic complications against COVID-19 with Vaxzevria (AstraZeneca) or with COVID-19 Vaccine Janssen (Johnson & Johnson) “.
More often – continues the note – the pain is getting worse, progressively increasing over a couple of days, but at other times it can reach maximum intensity in a very short time.
However, the AIFA specifies that: “The second dose of AstraZeneca vaccine is safe”. Clarification following the news on the in-depth document on post-vaccination thromboembolic complications with the AstraZeneca and J&J vaccines, released today by the same Agency. Aifa also invites us to “complete the vaccination which represents the best strategy to combat the Covid 19 virus and guarantees the best level of protection from the disease”.
Aifa, thrombosis with AZ and J&J not more frequent than average
Venous thromboembolic events in subjects vaccinated with Vaxzevria and the Janssen vaccine ‘were not more frequent than those expected in the unvaccinated population. However, rare cases of completely peculiar events characterized by thrombosis of the cerebral venous sinuses and / or thrombosis of the splanchnic veins have been ascertained ». Aifa notes this. As of April 4, a total of 222 rare thromboses of these types have been reported out of a total of approximately 34 million doses of Vaxzevria vaccine administered in the Eu and Gb Economic Area. In Italy on 26/4 34 cases of venous thrombosis are reported (0.45 per 100 thousand vaccinated).
Aifa: questions and answers on complications after the Astrazeneca and Johnson vaccines
In these latter situations, they also associate nausea and vomiting, photophobia, diplopia, decreased vision or loss of consciousness.
Other clinical manifestations of TSVC, on the other hand, can be represented by seizures, present at onset or after the onset of headache and neurological deficits similar to those seen after an ischemic stroke. It should not be forgotten, in fact, that thrombosis of the cerebral venous sinuses is classified both among the rare forms of venous thrombosis and among the rare forms of stroke. They should always be suspected in the presence of side neurological deficits in young subjects, especially if preceded or associated with headache.
Here is the in-depth document published by AIFA
Even in thrombosis of the abdominal veins the most common symptom is pain, often widespread and particularly intense. It can be associated with nausea and loss of appetite. Other times it is associated with gastrointestinal bleeding, especially with the emission of stools mixed with blood.
In the presence of one or more of the symptoms described above onset in the days following the administration of the vaccine, and in particular if around 7-21 days, especially when the pain is particularly intense and / or is associated with other symptoms or signs, the patient should be subjected to diagnostic tests quickly.
If presentation is important, it is essential to immediately send the patient to the emergency room informing of the recent vaccination. It is understood that if the clinical picture is doubtful due to symptoms of mild intensity or already accused prior to vaccination, careful monitoring of the clinical progress is recommended.
Aifa: The second dose of the AstraZeneca vaccine is safe
“The second dose of AstraZeneca vaccine is safe.” This is what the Italian Medicines Agency (Aifa) specifies following the news on the in-depth document on post-vaccination thromboembolic complications with the AstraZeneca and J & amp; J vaccines, released today by the same Agency. Aifa also invites us to “complete the vaccination which represents the best strategy to combat the Covid 19 virus and guarantees the best level of protection from the disease”.
With AstraZeneca’s anti-Covid vaccine, Vaxzevria, wrote Aifa, “it cannot be excluded that a subject who has not developed the rare reaction involving platelets with the first dose, cannot do so with the second”. Aifa notes this in an in-depth document on post-vaccination thromboembolic complications with the AstraZeneca and J&J vaccines. As of May 12, 15 cases of atypical thrombosis with thrombocytopenia were reported in GB out of about 9 million second Vaxzevria doses administered, therefore a “very rare” phenomenon. No information is currently available on the age and sex of these latter cases.
Aifa: AZ under-60 security uncertainties but complete reminders
The “safety of the administration of Vaxzevria in subjects under the age of 60 remains an open issue, and on which there are margins of uncertainty”. Despite these uncertainties, the Aifa Hemostasis and Thrombosis Working Group believes that the completion of the vaccination schedule with the second dose of Vaxzevria in under-60s who have already taken the first dose “represents the strategy to combat the spread of the SarsCoV2 virus. which guarantees the best level of protection “. Thus Aifa in a document on post-vaccination thromboembolic complications with the AstraZeneca and J&J vaccines.
© All rights reserved